Hemangiosarcoma

Antech’s breakthrough cancer screening tool launches in Europe, supporting early canine cancer detection

Retrieved on: 
Tuesday, April 23, 2024
Oncology, Health, Medical Devices, Genetics, Radiology, Biotechnology, Veterinary, Cancer, Veterinarian, Disease, EDTA, Lymphoma, DVM, Volition, Hemangiosarcoma, Diagnosis, Nucleosome, Dog, Plasma, Element, Vaccine

A rapid, accurate, targeted cancer screening tool for high-risk breeds and older dogs, Nu.Q® testing also includes prevalent types of canine cancers, enabling veterinarians and pet owners to make informed decisions about cancer care more quickly.

Key Points: 
  • A rapid, accurate, targeted cancer screening tool for high-risk breeds and older dogs, Nu.Q® testing also includes prevalent types of canine cancers, enabling veterinarians and pet owners to make informed decisions about cancer care more quickly.
  • Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech, part of Mars Science & Diagnostics said: “It’s exciting to see innovations like Nu.Q® Canine Cancer Test become more widely available to veterinary teams in Europe.
  • This is what our work at Antech is all about.”
    Nu.Q® Canine Cancer Test is a breakthrough technology that measures circulating nucleosomes, supporting earlier cancer detection in some of the most prevalent types of canine cancers.
  • ECVS, Tierklink Düsseldorf , used Nu.Q® Canine Cancer Test first-hand during the pilot phase and commented: “At our clinic, we see around 1500 cases of cancer in dogs a year.

Antech’s Breakthrough AI-powered Radiology and Targeted Cancer Screening Tools Now Available, Unleashing New Chapter for Veterinary Diagnostics

Retrieved on: 
Friday, April 12, 2024
Veterinary, Radiology, Biotechnology, Oncology, Health, Artificial Intelligence, Medical Devices, Technology, Veterinarian, Disease, EDTA, Lymphoma, DVM, VCA Animal Hospitals, Machine learning, Volition, Hemangiosarcoma, Diagnosis, AIS, Dog, Lifting, Cancer, Veil, Plasma, Element, Medical imaging

Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the availability of two new breakthrough innovations to mark a new chapter for veterinary diagnostics.

Key Points: 
  • Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the availability of two new breakthrough innovations to mark a new chapter for veterinary diagnostics.
  • The webinar will be offered May 21 and 22, and veterinary professionals can sign up here on Antech’s website.
  • Also now available is Nu.Q® Canine Cancer Test, a rapid, accurate, targeted cancer screening tool for high-risk breeds and older dogs.
  • Nu.Q® cancer detection includes prevalent types of canine cancers enabling veterinarians and pet owners to make informed decisions about cancer care more quickly.

Novel lower-cost blood test for cancer screening in dogs validated in large clinical study by PetDx

Retrieved on: 
Friday, February 9, 2024
Carcinoma, SAN, Cancer, American Veterinary Medical Association, Liquid biopsy, Leukemia, Lymphoma, DNA, Risk, Hemangiosarcoma, Journal, Osteosarcoma, Veterinary medicine, Dog, Histiocytic sarcoma, JAVMA, Medical imaging

SAN DIEGO, Feb. 9, 2024 /PRNewswire/ -- PetDx® – The Liquid Biopsy Company for Pets™ published a clinical validation study this week showing that its new OncoK9® Screen test has a high detection rate across seven predefined, clinically relevant cancer types that represent a large proportion of all cancers found in dogs and are often difficult to detect by physical exam alone due to their anatomic location and/or lack of specific clinical signs. These cancer types are often aggressive, requiring prompt intervention, and have typically been associated with improved outcomes when detected and treated early.

Key Points: 
  • By integrating cell-free DNA quantification and next-generation sequencing using a proprietary method, the new test can be performed faster and at lower cost than the company's flagship OncoK9® Dx test, allowing for broader access to blood-based cancer screening in dogs.
  • These cancer types are often aggressive, requiring prompt intervention, and have typically been associated with improved outcomes when detected and treated early.
  • "Previously published research has shown that only around 10% of cancer cases are currently detected in dogs prior to the onset of clinical signs.
  • "The availability of comprehensively validated blood-based cancer detection tools that can be readily incorporated into preventive care protocols opens the door to the development of cancer screening guidelines for early cancer detection in dogs."

Antech launches breakthrough in-hospital innovation, Nu.Q® Canine Cancer Test

Retrieved on: 
Friday, January 12, 2024
Element, Hemangiosarcoma, VMX, Volition, EDTA, Dog, Science, Pet, Cancer, Lymphoma, Plasma, Disease, DVM, Transport, Nucleosome, Telehealth, Veterinarian

ORLANDO, Fla., Jan. 12, 2024 /PRNewswire/ -- Antech, the veterinary diagnostics company focused on helping veterinary professionals predict, diagnose and monitor wellness and disease, today announced it will launch the breakthrough in-hospital Nu.Q® Canine Cancer Test at this year's annual VMX meeting.

Key Points: 
  • ORLANDO, Fla., Jan. 12, 2024 /PRNewswire/ -- Antech, the veterinary diagnostics company focused on helping veterinary professionals predict, diagnose and monitor wellness and disease, today announced it will launch the breakthrough in-hospital Nu.Q® Canine Cancer Test at this year's annual VMX meeting.
  • Nu.Q ® is a breakthrough technology that measures circulating nucleosomes, supporting earlier cancer detection in some of the most prevalent types of canine cancers.
  • To learn more about the in-hospital Nu.Q ®, visit booth 1522 at VMX 2024 or speak to your local Antech representative.
  • The Nu.Q® Canine Cancer Test is supplied to Antech's Heska affiliate under license by Belgian Volition SRL.

INTRODUCING HEMANGIO.COM: EMPOWERING PET OWNERS IN THE BATTLE AGAINST HEMANGIOSARCOMA

Retrieved on: 
Wednesday, November 1, 2023
Knowledge, Veterinarian, Hemangiosarcoma, Hope, Face, Research, Database, Disease, Cancer, Collection, Dog, Diagnosis, Pharmaceutical industry, Vaccine, Medical imaging

EAST HAMPTON, N.Y., Nov. 1, 2023 /PRNewswire/ -- As we mark Canine Cancer Awareness Month in November, a newly launched website, Hemangio.com, is set to revolutionize the way pet owners approach and understand hemangiosarcoma, a prevalent and aggressive form of cancer in dogs. Backed by the Canine Cancer Foundation, Inc., a non-profit dedicated to canine cancer research, this online platform aims to empower pet owners with knowledge, resources, and support when faced with a hemangiosarcoma diagnosis.

Key Points: 
  • Through Hemangio.com, pet owners will find a wealth of valuable information, including articles, clinical studies, videos, and clinical trials, all focused on hemangiosarcoma.
  • Clinical Trials Database: A valuable database of clinical trials for hemangiosarcoma is available for pet owners seeking innovative treatments for their furry family members.
  • Pet Owner Resources: Hemangio.com provides guidance on how pet owners can navigate the challenging journey of a hemangiosarcoma diagnosis.
  • Hemangio.com aspires to not only inform and educate but to create a community of support and hope for pet owners facing the challenges of hemangiosarcoma.

Morris Animal Foundation announces call for canine hemangiosarcoma research proposals

Retrieved on: 
Friday, January 13, 2023
Heart, Disease, Canine cancer detection, Bleeding, Spleen, RFP, Dog, Golden, Morris Animal Foundation, Vaccine, Pharmaceutical industry, Hemangiosarcoma

DENVER, Jan. 13, 2023 /PRNewswire/ -- Morris Animal Foundation is now accepting proposals that will catalyze development of new tools to prevent, detect and treat canine hemangiosarcoma.

Key Points: 
  • DENVER, Jan. 13, 2023 /PRNewswire/ -- Morris Animal Foundation is now accepting proposals that will catalyze development of new tools to prevent, detect and treat canine hemangiosarcoma.
  • "Hemangiosarcoma is a devastating canine cancer, and the Golden Retriever Lifetime Study has seen an exceptionally high rate of this disease," said Dr. Kathy Tietje, Morris Animal Foundation Vice President, Scientific Operations.
  • Hemangiosarcoma is one of the deadliest forms of canine cancer.
  • The average survival time for dogs diagnosed with hemangiosarcoma, even with treatment, is four to six months.

Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network

Retrieved on: 
Thursday, January 12, 2023
Animal, Laboratory, Texas A&M University, Lymphoma, Nu, Idexx Laboratories, Veterinarian, Volition, Trial of the century, Dog, Health, NYSE, Hemangiosarcoma, Professor, Histiocyte, Cancer, Human, PETS, Pharmaceutical industry, Vaccine, Medical device

It is a simple, cost effective, easy to use blood test for screening older or 'at risk' dogs.

Key Points: 
  • It is a simple, cost effective, easy to use blood test for screening older or 'at risk' dogs.
  • "Our Nucleosomics™ technology is easy to incorporate into annual wellness visits to support veterinarians in their clinical decision-making, enable earlier detection and treatment of cancer and improve the health and wellbeing of pets and pet owners.
  • Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals.
  • Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test.

Volition Announces Clinical Research Study with Oncovet

Retrieved on: 
Monday, November 14, 2022
Securities Act of 1933, Lymphoma, Quality of life, Cancer, Technology, U.S. Securities and Exchange Commission, Radiation, Security (finance), Cardiology, Oncology, Dog, Animal, Forward-looking statement, Veterinarian, Histiocytic sarcoma, Cat, Name, Texas A&M University, Research, NYSE, Trial of the century, Securities Exchange Act of 1934, Internal medicine, Annual report, Patient, Failure, Volition (linguistics), COVID-19, Hemangiosarcoma, Human, Sepsis, Life, Professor, Science, Diagnosis, Disease, Neutrophil extracellular traps, Veterinary medicine, Medical device, Nucleosome, Volition

HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.

Key Points: 
  • HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.
  • The non-interventional study is being led by Dr. Jrme Benoit, Oncovet's Clinical Director, and will evaluate circulating nucleosomes of dogs and cats with cancer using Volition's Nu.Q Vet Cancer Test.
  • Dr. Jrme Benoit, Clinical Director at Oncovet, said: "Volition's Nu.Q Vet Cancer Test has already been shown to detect systemic cancers in dogs such as lymphoma and hemangiosarcoma.
  • Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: "We are delighted to collaborate with Dr. Benoit and his team on this research study.

Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

Retrieved on: 
Thursday, November 3, 2022
NASDAQ, Lymphoma, Security (finance), Veterinarian, U.S. Securities and Exchange Commission, Forward-looking statement, Software, COVID-19, Dog, Securities Act of 1933, Neutrophil extracellular traps, Trial of the century, Professor, Sepsis, Research, HSKA, Technology, Achievement, PETS, Texas A&M University, Name, Patient, Quality of life, Cancer, Annual report, Animal, Hemangiosarcoma, Immunotherapy, Science, Life, Health, License, Volition (company), Disease, NYSE, Histiocytic sarcoma, Securities Exchange Act of 1934, Human, Pharmaceutical industry, Medical device, International, Volition, Nucleosome

The accurate, affordable, and non-invasive diagnostic for cancer screening and monitoring in canines is an ideal fit within Heska's expanding portfolio of best-in-class solutions.

Key Points: 
  • The accurate, affordable, and non-invasive diagnostic for cancer screening and monitoring in canines is an ideal fit within Heska's expanding portfolio of best-in-class solutions.
  • Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said, "We're thrilled to be working alongside Heska and support the launch of the Nu.QVet Cancer Screening Test in the United States and Europe.
  • Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals.
  • All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

Morris Animal Foundation Launches Research Initiative into Leading Cause of Canine Cancer Deaths

Retrieved on: 
Wednesday, November 2, 2022
Veterinarian, Dog, Canine cancer detection, Morris Animal Foundation, Research, United States Air Force Scientific Advisory Board, RFP, View, Foundation, Golden, Multimedia, Pharmaceutical industry, Hemangiosarcoma

DENVER, Nov. 2, 2022 /PRNewswire/ -- Morris Animal Foundation announced a new multimillion-dollar research initiative focused on hemangiosarcoma, the leading cause of cancer deaths in the Golden Retriever Lifetime Study.

Key Points: 
  • DENVER, Nov. 2, 2022 /PRNewswire/ -- Morris Animal Foundation announced a new multimillion-dollar research initiative focused on hemangiosarcoma, the leading cause of cancer deaths in the Golden Retriever Lifetime Study.
  • "Hemangiosarcoma, an almost universally fatal cancer, accounts for approximately 70% of cancer deaths to date in our study cohort," said Dr. Kathy Tietje, Vice President of Scientific Operations at Morris Animal Foundation.
  • All proposals submitted to Morris Animal Foundation in response to this RFP will undergo administrative and scientific review by a Scientific Advisory Board.
  • Interested researchers can find additional information, including award types and funding levels at Morris Animal Foundation Apply for a Grant.